IL135284A - Method and reagents for n-alkylating ureides - Google Patents

Method and reagents for n-alkylating ureides

Info

Publication number
IL135284A
IL135284A IL13528498A IL13528498A IL135284A IL 135284 A IL135284 A IL 135284A IL 13528498 A IL13528498 A IL 13528498A IL 13528498 A IL13528498 A IL 13528498A IL 135284 A IL135284 A IL 135284A
Authority
IL
Israel
Prior art keywords
reagents
ureides
methoxymethyl
alkylating
alkylating ureides
Prior art date
Application number
IL13528498A
Other languages
English (en)
Inventor
Daniela Gutman
Hershel Herzog
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of IL135284A publication Critical patent/IL135284A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL13528498A 1997-10-02 1998-10-02 Method and reagents for n-alkylating ureides IL135284A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/942,636 US6093820A (en) 1997-10-02 1997-10-02 Method and reagents for N-alkylating ureides

Publications (1)

Publication Number Publication Date
IL135284A true IL135284A (en) 2005-11-20

Family

ID=25478386

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13528498A IL135284A (en) 1997-10-02 1998-10-02 Method and reagents for n-alkylating ureides
IL16508004A IL165080A0 (en) 1997-10-02 2004-11-07 Method and reagents for n-alkylating ureides

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16508004A IL165080A0 (en) 1997-10-02 2004-11-07 Method and reagents for n-alkylating ureides

Country Status (13)

Country Link
US (4) US6093820A (zh)
EP (2) EP1027339B1 (zh)
JP (2) JP4061018B2 (zh)
CN (2) CN1193019C (zh)
AT (2) ATE299500T1 (zh)
AU (1) AU758506B2 (zh)
CA (1) CA2304970C (zh)
DE (2) DE69820895T2 (zh)
DK (2) DK1342718T3 (zh)
ES (2) ES2243833T3 (zh)
IL (2) IL135284A (zh)
PT (2) PT1027339E (zh)
WO (1) WO1999018084A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CN1291720C (zh) * 2002-01-30 2006-12-27 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR042444A1 (es) * 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
US7122542B2 (en) * 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
DK1856135T3 (da) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
US8853257B2 (en) 2005-11-21 2014-10-07 Mordechai Sharir Succinimide derivatives as ocular hypotensive agents
JP2009516677A (ja) * 2005-11-21 2009-04-23 シャリール、モルデチャイ 眼圧降下剤としてのスクシンイミド誘導体
US20080132529A1 (en) * 2006-11-14 2008-06-05 Avraham Yacobi Method of improving bioavailability for non-sedating barbiturates
KR20130056912A (ko) 2010-10-27 2013-05-30 더 질레트 컴퍼니 비-발포성 수화 조성물을 포함하는 조성물 분배 장치
US20120278179A1 (en) * 2011-04-28 2012-11-01 Ray Campbell Systems and methods for deducing user information from input device behavior
US20130205959A1 (en) 2011-08-16 2013-08-15 Neil John Jones Composition Dispensing Device Comprising A Moisturizing Composition
SG10201803685TA (en) 2013-11-01 2018-06-28 Gillette Co Llc Shave care composition for a liquid dispensing razor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
AR204518A1 (es) * 1973-02-28 1976-02-12 Kendall & Co Procedimiento para preparar n-mono(alcoximetil)fenobarbital
DE2622981A1 (de) * 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
DE4028040A1 (de) * 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
US6184238B1 (en) 1996-12-26 2001-02-06 Nikken Chemicals Co., Ltd. N-hydroxyurea derivative and pharmaceutical composition containing the same
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CA2331735A1 (en) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
JP2002516315A (ja) 1998-05-26 2002-06-04 ナチュラル ドラッグ サイエンシズ，リミティド ライアビリティ カンパニー ５−オキシミノバルビツール酸のｎ−置換誘導体
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
DE60132337T2 (de) 2000-07-26 2009-02-12 Taro Pharmaceutical Industries Ltd. Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Also Published As

Publication number Publication date
EP1342718A1 (en) 2003-09-10
AU9597698A (en) 1999-04-27
USRE38934E1 (en) 2006-01-10
DK1342718T3 (da) 2005-09-26
CN1699349A (zh) 2005-11-23
WO1999018084A1 (en) 1999-04-15
JP2008101002A (ja) 2008-05-01
DK1027339T3 (da) 2004-05-03
JP4061018B2 (ja) 2008-03-12
EP1342718B1 (en) 2005-07-13
US6906079B2 (en) 2005-06-14
DE69830860T2 (de) 2006-04-27
CN1193019C (zh) 2005-03-16
AU758506B2 (en) 2003-03-20
ATE257153T1 (de) 2004-01-15
ES2243833T3 (es) 2005-12-01
US20040167358A1 (en) 2004-08-26
CN1273581A (zh) 2000-11-15
DE69820895T2 (de) 2004-10-28
DE69830860D1 (de) 2005-08-18
EP1027339B1 (en) 2004-01-02
PT1342718E (pt) 2005-11-30
CA2304970C (en) 2010-07-13
CA2304970A1 (en) 1999-04-15
JP2001519334A (ja) 2001-10-23
IL165080A0 (en) 2005-12-18
PT1027339E (pt) 2004-05-31
DE69820895D1 (de) 2004-02-05
US6664262B2 (en) 2003-12-16
US6093820A (en) 2000-07-25
ATE299500T1 (de) 2005-07-15
ES2214736T3 (es) 2004-09-16
EP1027339A1 (en) 2000-08-16
US20030018080A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
IL165080A0 (en) Method and reagents for n-alkylating ureides
DK0871631T3 (da) Antiparasitære marcfortiner og paraherquamider
IL132249A0 (en) Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
HK1046004A1 (en) Recombinant gelatins
IL137726A0 (en) Bronic ester and acid compounds
PH25056A (en) 4,5,6-substituted-n-(substituted-phenyl)-2-pyrimidinamines
GR980300076T1 (en) Estrogen receptor
BG105028A (en) Bridged indenopyrrolocarbazoles
WO1998028317A3 (en) Synthesis of nucleosides and polynucleotides
IL135648A0 (en) Novel 3, 6-hemiketals from the class of 9a-azalides
IL126989A (en) Process for making 4,6-dihydroxypyrimidine
ATE285474T1 (de) Haemophilus adhäsionsproteinen
ID19571A (id) Proses pemurnian 1,4-butanadiol mentah
MX9706744A (es) Proceso novedosos para preparar derivados de 2,3-dihidro-benzofuranol.
WO1997035015A3 (de) Tyrosin-phosphatase-verwandtes protein
EP0974577A4 (en) METHOD FOR PRODUCING 4,6-BIS (SUBSTITUTED) PHENYLAZORESORCINOLS
ID16030A (id) Proses pembuatan turunan 1,5-benzotiazepin
PL321482A1 (en) Method of obtaining 2,6-bis/picrylamino/3,4-dinitrilpyridine
ZA981280B (en) Novel process.
PL321483A1 (en) Method of obtaining 2,6-bis/picrylamino/3,4-dinitrilpyridine
ZA966379B (en) Novel process.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees